MIACH Orthopaedics, a bioengineered surgical implant company, completed $22.5 million in financing.
Here are four things to know:
1. The series A financing round was co-led by Amzak Health Investors and DSM Venturing. The NFL Players Association and additional investors also participated.
2. The company will use the proceeds to continue FDA-approved clinical trials of its first implant, the Bridge-Enhanced ACL Repair. The BEAR implant is designed to facilitate healing of a torn anterior cruciate ligament.
3. The BEAR technology is a proprietary bioengineered sponge used as a bridging scaffold to stimulate healing. It has been tested in nearly 100 patients.
4. According to Martha Murray, MD, founder of MIACH Orthopaedics and orthopedic surgery professor at Boston-based Harvard Medical School, the company will also use the funds to accelerate "clinical trials to further evaluate the less-invasive BEAR technology as a viable alternative to ACL reconstruction."